Get started
SPDR Series Trust SPDR S&P Biotech ETFSPDR Series Trust SPDR S&P Biotech ETFSPDR Series Trust SPDR S&P Biotech ETF

SPDR Series Trust SPDR S&P Biotech ETF

No trades
See on Supercharts
Overview Analysis Holdings News
Ideas
Discussions Technicals Seasonals Options

XBI trade ideas

$XBI - Fundamentally Undervalued, Strong Bounce Off Of SupportI posted the wrong chart when doing my analysis on this ticker last time, so I'm here to update my error! This is a very interesting sector to keep an eye on after it's gotten relentlessly hammered for the past six months. There are now over 100 biotech stocks selling below cash, meaning these companies literally have more cash on their balance sheet than their entire market cap! Furthermore, there are 300 additional biotech stocks selling at 1/2 cash (50% of their balance sheet is at least half of their current market cap). There are an insane amount of bargains within this sector, and the entire sector is poised to make a reversal after a strong bounce off of support, and bullish engulfing candle on the daily. I wouldn't be surprised to see this entire batch of stocks start to perform very well over the following months. A trip back to the 130s is almost inevitable.
AMEX:XBILong
by FluxTrades
3
$XBI - Fundamentally Undervalued, Strong Bounce Off Of SupportThis is a very interesting sector to keep an eye on after it's gotten relentlessly hammered for the past six months. There are now over 100 biotech stocks selling below cash, meaning these companies literally have more cash on their balance sheet than their entire market cap! Furthermore, there are 300 additional biotech stocks selling at 1/2 cash (50% of their balance sheet is at least half of their current market cap). There are an insane amount of bargains within this sector, and the entire sector is poised to make a reversal after a strong bounce off of support, and bullish engulfing candle on the daily. I wouldn't be surprised to see this entire batch of stocks start to perform very well over the following months. A trip back to the 130s is almost inevitable.
AMEX:XBILong
by FluxTrades
Biotech primed for a move higher?This one is almost pure intuition. We're in pharmaceuticals earnings season now. Seagen reports after market today. A bunch of other large holdings of XBI report on November 3-4, and a bunch more on November 8. Bonds and tech stocks have made a breakout move upward, and small caps look primed. (XBI is full of small and micro caps.) XBI has had a long consolidation here, and I really like the price action on it today. A lot of other sector funds have had mid-day pullbacks, but XBI has maintained its steady upward slope. It has poked above the 20-day EMA. My guess is that this will be green again tomorrow, so I've rolled the dice on a call expiring October 29. I'm also looking for continuation the next two weeks, with a first target of about 131.75.
AMEX:XBILong
by ChristopherCarrollSmith
17
The biotech sector may be a big winner into the year’s endThe $XBI has been one of the worst performing ETFs this year as the biotech sector faced important headwinds coming from Washington. A cap on prices has been since dropped, which is extremely beneficial for the long term. In addition, from a historical perspective, November and December are this ETF’s strongest months. The candidates for the Ash conference of biotechs will be announced this week which may prove to be yet another positive catalyst. We are long some $XBI calls for January and continue to hold our small bio spec play, $MBIO.
AMEX:XBILong
by Eclubtrading